Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

C6 Glioma Cell¿¡ ´ëÇÑ TamoxifenÀÇ È¿°ú Effect of Tamoxifen in C6 Glioma Cells

´ëÇѽŰæ¿Ü°úÇÐȸÁö 1997³â 26±Ç 1È£ p.5 ~ 10
¼Ò¼Ó »ó¼¼Á¤º¸
À¯È¯Á¾/Chan Jong Yoo À̾ð/±è¿µº¸/°­µ¿¼ö/¹Úö¿Ï/À¯¿µ¹Ì/Uhn Lee/Young Bo Kim/Dong Soo Kang/Chuel Wan Park/Young Mi Yoo

Abstract

¼­ ·Ð
½Å°æ ±³Á¾Àº ³úÁ¾¾ç¿¡¼­ ¾à ¹Ý¼ö¸¦ Â÷ÁöÇÏ´Â °¡Àå ÈçÇÑ Á¾¾çÀ̸ç ÀÌÁß ¼º»ó ¼¼Æ÷ Á¾¾ç
(astrocytic tumor ; astrocytoma, anaplastic astrocytoma. glioblastoma)ÀÌ ´ëºÎºÐÀ» Â÷ÁöÇÏ
°í ÀÖ°í, ´ÙÇü¼º ±³¾Æ ¼¼Æ÷Á¾(glioblsatoma)ÀÌ ¹Ý¼ö¸¦ Â÷ÁöÇÏ°í ÀÖ´Ù Russell°ú RubinsteinÀº
¶óÇü¼º ±³¾Æ¼¼Æ÷Á¾Àº ¼º»ó ¼¼Æ÷Á¾¿¡¼­ ¸Å¿ì µå¹® ȸµ¹±â ±³¼¼Á¾º¸´Ù ¼ºÀå ¼¼Æ÷Á¾°ú ȸµ¹±â
±³¼¼Á¾ÀÌ ÀüÀÎ Á¾¾ç¿¡¼­ Á¡Â÷ÀûÀ¸·Î ¿ªºÐÈ­µÇ°í »ý±ä´Ù°í ¹àÇû´Ù. ¼º»ó ¼¼Æ÷Á¾¿¡¼­ ¾Ç¼ºÈ­
µÇ´Â °úÁ¤Àº PETÀ̳ªMRI¿¡¼­ °üÂûµÉ ¼ö ÀÖ´Ù ½Å°æ±³Á¾Àº ÇöÀç±îÁöµµ ´Ù¸¥ Á¾¾ç¿¡¼­Ã³·³
¿øÀÎ ¹× Á¾¾ç Çü¼º °úÁ¤À» ¸ð¸£°í ÀÖ´Ù. 1970³â´ëºÎÅÍ ¸¹ÀÌ ¿¬±¸µÇ¾î ¿Ô´ø ¼¼Æ÷¿ªÇÐ ¿¬±¸
´öºÐ¿¡ À̵é Á¾¾çÀÇ ¿¹ÈÄ Ä¡·á¿¡ µµ¿òÀ» ÁÙ ¼ö ÀÖ¾ú°í Á¾¾çÀÇ ¼ºÀåÀ» ¸¹ÀÌ ÀÌÇØÇÏ°Ô ÇǾú´Ù
ÃÖ±Ù ºÐÀÚ »ý¹°ÇÐÀÇ ¹ßÀüÀ¸·Î À̵é Á¾¾ç¿¡ ´ëÇÑ ¿¬±¸°¡ ¸¹ÀÌ ¼öÇàµÇ¾îÁö°í ÀÖ´Ù. Áï ¼ºÀåÀÎ
ÀÚ¾Ï À¯ÀüÀÚ, ¾Ï ¾ïÁ¦ À¯ÀüÀÚ, Ç÷°ü Çü¼º ÀÎÀÚ µî ¸¹Àº ¿¬±¸°¡ ¹ßÇ¥µÇ¾úÁö¸¸ ÀÓ»ó¿¡ ÀûÀÀÇÏ
±â¿¡´Â ¾ÆÁ÷ ´õ ¸¹Àº ¿¬±¸°¡ ÀÌ·ç¾îÁ®¾ßÇÑ´Ù ¼ö¼ú, ¹æ»ç¼± ¿ä¹ý°ú È­ÇÐÀû ¿ä¹ýÀ¸·Î Ä¡·áÇÔ
¿¡µµ ºÒ±¸ÇÏ°í ¾Ç¼º ½Å°æ±³Á¾À» Áö´Ñ ÇÑÀÚ¿¡ ´ëÇÑ °á°ú´Â ÁÁÁö ¾Ê¾Ò´Ù. ±× ÀÌÀ¯ÁßÀÇ Çϳª´Â
¹ß»ç¼± ¶Ç´Â È­ÇÐÀû ¿ä¹ý¿¡ ´ëÇÏ¿© glioma°¡ ³»¼ºÀ» °®´Â´Ù´Â °ÍÀÌ´Ù. ½Å°æ±³Á¾ÀÇ Ä¡·á¿¡
´ëÇÑ Áß¿äÇÑ ¸ñÇ¥´Â Ç×¾ÏÁ¦¿Í ¹æ»ç¼± Á¶»ç¿¡ ´ëÇÑ ¼¼Æ÷ÇÐÀû ¹Î°¨µµ(cellular sensitively)¸¦
Áõ°¡½ÃÅ°´Â °ÍÀÌ´Ù. Non-steroidal antiestrogenic È­ÇÕ¹°ÀÎ TamoxifenÀÌ in vitroÀÇ ½Å°æ±³
Á¾À» Æ÷ÇÔÇÑ estrogen receptor-negative cell lineµéÀÇ Áõ°¡¸¦ ¾ïÁ¦ÇÏ¿© À¯¹æ¾Ï(human
hi-east cancer)ÀÇ Ä¡·á¿¡ ¸¹ÀÌ »ç¿ëµÇ¾îÁö°í ÀÖ´Ù. TamoxifenÀº µ¶¼ºÀÌ »ó´ëÀûÀ¸·Î ³·¾Æ
10³â ÀÌ»ó ÀÓ»óÀû Ä¡·á¸¦ ÇàÇÏ¿´À¸³ª. ÀÌ°ÍÀÇ ÀÛ¿ë ¸ÞÄ«´ÏÁòÀº ¿ÏÀüÇÏ°Ô ¾Ë·ÁÁø »óÅ´ ¾Æ
´Ï´Ù. Tamoxifen metabolismÀÇ ±Ùº»ÀûÀÎ ¿¬±¸¿¡¼­´Â ÁÖ¿ä ½ÅÁø ´ë»ç °ü¿©¹°Áú·Î½á
4OHT(4-hydroxytamoxifen)À» µ¿Á¤ÇÏ¿´À¸³ª, ÃÖ±Ù ¿¬±¸¿¡¼­´Â talnoxifenÀ» Åõ¿©ÇÑ È¯ÀÚÀÇ
¾ÏÁ¶Á÷°ú Ç÷Àå¿¡ ÃàÀûµÈ ÁÖ¿ä ½ÅÁø ´ë»ç °ü¿©¹°ÁúÀº, »ó´çÈ÷ ³·Àº ³óµµÀÇ 40HT°¡ Á¸ÀçÇÔ°ú
¾Æ¿ï·¯, DMT (N-demethyltamoxifen)À¸·Î º¸°íµÇ°í ÀÖ´Ù. TamoxifenÀÇ ¾ïÁ¦È¿°ú´Â ¼¼Æ÷ÁÖ
±âÀÇ G0-G1 ½Ã±â¿¡¼­ ¼¼Æ÷³»ÀÇ ÃàÀû¿¡ ÀÇÇؼ­ ÀÌ·ç¾îÁö°í ÀÖ´Ù.
#ÃÊ·Ï#
This work describes tamoxifen, a nonsteroidal antiestrogen compound, which has been
used extensively in the treatment of breast cancer on account of its efficacy and
relatively low toxicity. It has been reported to inhibit glioma proliferation in all cell line
tested, acting by a mechanism independent of estrogen receptor blockade. Tamoxifen
causes cytotoxicity at higher concentration(¡Ã5¥ìM), as compared with control. Our
results showed that this compound decreased the rate of cell proliferation in
dose-dependent manner. Its treatment against the C6 glioma cells also
resulted in enhancement of the antitumor effect. These data suggest that tamoxifen may
serve as an useful agent in chemotherapy of glioma.

Å°¿öµå

C6; Tamoxifen.;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS